

March 22, 2025

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai – 400 001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra – Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Company has received a draft Order Giving Effect to the order of Hon'ble Income-tax Appellate Tribunal, being passed under section 144C(1) read with section 143(3) of the Income Tax Act, 1961 for assessment year 2014-15 on March 21, 2025.

The captioned order is a subsequent development in the ongoing litigations, which was disclosed to the stock exchanges vide our letter dated August 14, 2023.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking You

For AstraZeneca Pharma India Limited

Manasa R

Company Secretary

Annexure – A

Sl. No.	Particulars	Details
1.	Name of the opposing party	Assistant Commissioner of Income tax
2.	Brief details of dispute/litigation	Company has received a draft Order Giving Effect to the order of Hon'ble Income-tax Appellate Tribunal, being passed under section 144C(1) read with section 143(3) of the Income Tax Act, 1961 for assessment year 2014-15, wherein major adjustments done on the transfer pricing as well as corporate tax issues have been deleted.
3.	Court/tribunal/agency where the litigation is filed	The present order is a draft Order Giving Effect to the order of Hon'ble Income-tax Appellate Tribunal.
4.	Expected financial implications, if any, due to compensation, penalty etc	The quantum of tax relief as per the captioned order is Rs. 35.22 crores (approx.) excluding interest.
5.	Quantum of claims, if any	NA